Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
T62099 |
LSD1-IN-13
|
||
LSD1-IN-13 (compound 7e) 是一种口服具有活力的 LSD1 抑制剂 (IC50: 24.43 nM),也能够激活 CD86 表达 (EC50: 470 nM)。LSD1-IN-13 可以诱导 AML (急性髓系白血病) 细胞系分化。 | |||
T62679 |
LSD1-IN-13 hydrochloride
|
||
LSD1-IN-13 hydrochloride (compound 7e) 是一种口服具有活力的 LSD1 抑制剂 (IC50: 24.43 nM)。LSD1-IN-13 hydrochloride 能够激活 CD86 表达 (EC50: 470 nM)。LSD1-IN-13 hydrochloride 可以诱导 AML (急性髓系白血病) 细胞系分化。 | |||
T77635 |
LSD1-IN-27
|
Histone Demethylase; PD-1/PD-L1 | Apoptosis; Cell Cycle/Checkpoint; Chromatin/Epigenetic; Immunology/Inflammation |
LSD1-IN-27 是一种高效的 LSD1 抑制剂 ,IC50 值为 13 nM。LSD1-IN-27 对胃癌细胞的干细胞性和迁移有抑制作用。LSD1-IN-27 对 BGC-823 和 MFC 细胞中 PD-L1 的表达有抑制作用。LSD1-IN-27 可增强对胃癌的 T 细胞免疫反应。 | |||
T61768 | FY-56 | ||
FY-56 是一种高效的具有选择性LSD1/KDM1A 抑制剂 (IC50=42 nM),比 MAO-A/B 具有高选择性. FY-56 诱导 MOLM-13 和 MV4-11 细胞分化,具有急性髓系白血病 AML 研究潜力。 | |||
T39439 |
Seclidemstat mesylate
SP-2577 mesylate |
||
Seclidemstat mesylate (SP-2577) is a highly effective and reversible inhibitor of KDM1A (LSD1), with a Ki of 31 nM and an IC 50 of 13 nM. It demonstrates significant potential in promoting antitumor immunity in switch/sucrose nonfermentable (SWI/SNF) complex mutated ovarian cancer, while also exhibiting inhibitory effects on virus production, viral DNA replication, and late gene expression. Seclidemstat mesylate is a valuable tool for studying Ewing Sarcoma in research settings. |